Takeda Pharmaceutical Company Limited (NYSE:TAK) Shares Purchased by Forum Financial Management LP

Forum Financial Management LP increased its stake in Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 133.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 114,324 shares of the company's stock after purchasing an additional 65,399 shares during the period. Forum Financial Management LP's holdings in Takeda Pharmaceutical were worth $1,514,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Marshall Wace LLP acquired a new position in shares of Takeda Pharmaceutical during the fourth quarter valued at $1,010,000. Mariner LLC grew its holdings in Takeda Pharmaceutical by 14.0% in the 4th quarter. Mariner LLC now owns 142,504 shares of the company's stock worth $1,887,000 after buying an additional 17,525 shares in the last quarter. Townsquare Capital LLC acquired a new stake in Takeda Pharmaceutical in the 4th quarter valued at approximately $151,000. Raymond James Financial Inc. bought a new stake in Takeda Pharmaceutical during the 4th quarter valued at $1,447,000. Finally, Bank of Montreal Can boosted its position in Takeda Pharmaceutical by 8.9% during the 4th quarter. Bank of Montreal Can now owns 86,776 shares of the company's stock worth $1,149,000 after acquiring an additional 7,124 shares during the period. Institutional investors and hedge funds own 9.17% of the company's stock.

Takeda Pharmaceutical Price Performance

Shares of Takeda Pharmaceutical stock traded down $0.05 on Thursday, hitting $15.14. The company had a trading volume of 1,189,524 shares, compared to its average volume of 1,949,103. Takeda Pharmaceutical Company Limited has a 52 week low of $12.57 and a 52 week high of $15.37. The company has a market cap of $48.16 billion, a PE ratio of 37.84, a PEG ratio of 0.24 and a beta of 0.39. The business has a 50-day simple moving average of $14.67 and a 200-day simple moving average of $13.93. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.31 and a quick ratio of 0.72.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last issued its quarterly earnings results on Thursday, January 30th. The company reported $0.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. Research analysts expect that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley upgraded shares of Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a research note on Wednesday, April 2nd.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.